

Pedro Miguel Rodrigues

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/571311/publications.pdf>

Version: 2024-02-01

43
papers

4,613
citations

331259

21
h-index

264894

42
g-index

47
all docs

47
docs citations

47
times ranked

9610
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomewide Association Study of Severe Covid-19 with Respiratory Failure. <i>New England Journal of Medicine</i> , 2020, 383, 1522-1534.	13.9	1,548
2	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 557-588.	8.2	1,155
3	Delivering the promise of miRNA cancer therapeutics. <i>Drug Discovery Today</i> , 2013, 18, 282-289.	3.2	260
4	Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis. <i>Clinical Science</i> , 2015, 129, 721-739.	1.8	175
5	Metabolic rearrangements in primary liver cancers: cause and consequences. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 748-766.	8.2	144
6	Activation of necroptosis in human and experimental cholestasis. <i>Cell Death and Disease</i> , 2016, 7, e2390-e2390.	2.7	107
7	Efficient recovery of proteins from multiple source samples after trizol [®] or trizol [®] LS RNA extraction and long-term storage. <i>BMC Genomics</i> , 2013, 14, 181.	1.2	92
8	miRNA-21 ablation protects against liver injury and necroptosis in cholestasis. <i>Cell Death and Differentiation</i> , 2018, 25, 857-872.	5.0	92
9	Diagnostic and prognostic biomarkers in cholangiocarcinoma. <i>Liver International</i> , 2019, 39, 108-122.	1.9	89
10	miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice. <i>Cell Death and Disease</i> , 2017, 8, e2748-e2748.	2.7	78
11	Circulating microRNAs as Potential Biomarkers in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma. <i>Journal of Clinical Medicine</i> , 2016, 5, 30.	1.0	77
12	Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis. <i>Cells</i> , 2020, 9, 721.	1.8	63
13	Pathogenesis of Cholangiocarcinoma. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2021, 16, 433-463.	9.6	63
14	c-Jun N-Terminal Kinase 1/c-Jun Activation of the p53/MicroRNA 34a/Sirtuin 1 Pathway Contributes to Apoptosis Induced by Deoxycholic Acid in Rat Liver. <i>Molecular and Cellular Biology</i> , 2014, 34, 1100-1120.	1.1	61
15	TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms. <i>Gut</i> , 2021, 70, 1345-1361.	6.1	59
16	RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease. <i>Gut</i> , 2021, 70, 2359-2372.	6.1	56
17	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. <i>Human Molecular Genetics</i> , 2022, 31, 3945-3966.	1.4	46
18	Current and novel therapeutic opportunities for systemic therapy in biliary cancer. <i>British Journal of Cancer</i> , 2020, 123, 1047-1059.	2.9	37

#	ARTICLE	IF	CITATIONS
19	Primary biliary cholangitis: A tale of epigenetically-induced secretory failure?. <i>Journal of Hepatology</i> , 2018, 69, 1371-1383.	1.8	35
20	Diet-dependent gut microbiota impacts on adult neurogenesis through mitochondrial stress modulation. <i>Brain Communications</i> , 2020, 2, fcaa165.	1.5	27
21	Inhibition of NF- κ B by deoxycholic acid induces miR-21/PDCD4-dependent hepatocellular apoptosis. <i>Scientific Reports</i> , 2015, 5, 17528.	1.6	24
22	Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic liver disease: New therapeutic targets. <i>Liver International</i> , 2020, 40, 1670-1685.	1.9	22
23	Immune Checkpoint Inhibitors: The Emerging Cornerstone in Cholangiocarcinoma Therapy?. <i>Liver Cancer</i> , 2021, 10, 545-560.	4.2	22
24	TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation. <i>Journal of Hepatology</i> , 2022, 77, 991-1004.	1.8	22
25	Skeletal muscle miR-34a/SIRT1:AMPK axis is activated in experimental and human non-alcoholic steatohepatitis. <i>Journal of Molecular Medicine</i> , 2019, 97, 1113-1126.	1.7	21
26	Next-Generation Biomarkers for Cholangiocarcinoma. <i>Cancers</i> , 2021, 13, 3222.	1.7	20
27	Modulation of liver steatosis by miR-21/PPAR α . <i>Cell Death Discovery</i> , 2018, 4, 9.	2.0	15
28	The jigsaw of dual hepatocellular "intrahepatic cholangiocarcinoma tumours. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 653-655.	8.2	15
29	Cholangiocarcinoma progression depends on the uptake and metabolism of extracellular lipids. <i>Hepatology</i> , 2022, 76, 1617-1633.	3.6	15
30	Genetics, pathobiology and therapeutic opportunities of polycystic liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 585-604.	8.2	15
31	CXCR7 contributes to the aggressive phenotype of cholangiocarcinoma cells. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 2246-2256.	1.8	14
32	Efficacy and Safety of the Combination of Pravastatin and Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (ESTAHEP Clinical Trial). <i>Cancers</i> , 2020, 12, 1900.	1.7	14
33	Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models. <i>Journal of Hepatology</i> , 2021, 74, 394-406.	1.8	14
34	Live-cell imaging of p53 interactions using a novel Venus-based bimolecular fluorescence complementation system. <i>Biochemical Pharmacology</i> , 2013, 85, 745-752.	2.0	13
35	YAP Accelerates Notch-Driven Cholangiocarcinogenesis via mTORC1 in Mice. <i>American Journal of Pathology</i> , 2021, 191, 1651-1667.	1.9	12
36	Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models. <i>Journal of Hepatology</i> , 2022, 77, 177-190.	1.8	11

#	ARTICLE	IF	CITATIONS
37	Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease. <i>Hepatology</i> , 2021, 73, 186-203.	3.6	7
38	Inhibition of NAE-dependent protein hyperacetylation in cystic cholangiocytes halts cystogenesis in experimental models of polycystic liver disease. <i>United European Gastroenterology Journal</i> , 2021, 9, 848-859.	1.6	7
39	Characterizing the Heterogeneity of Liver Cell Populations Under a NASH-Related Hepatotoxicant Using Single-Nuclei RNA Sequencing. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 294-296.	2.3	3
40	Editorial: bezafibrate in the treatment of patients with primary biliary cholangitis "are we there yet?". <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 247-248.	1.9	3
41	Applications of organoids in regenerative medicine: a proof-of-concept for biliary injury. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 371-372.	8.2	2
42	Unscrambling a novel pathogenic role for interleukin-20 in acute hepatitis and bacterial infection: A double-edged sword?. <i>Journal of Hepatology</i> , 2021, 75, 22-24.	1.8	0
43	A look back at cholangiocarcinoma in Finland. <i>United European Gastroenterology Journal</i> , 2021, 9, 1103-1104.	1.6	0